InsiderTrades.com logo

CYTH Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 29.78%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Share Price & Price History

Current Price: $0.72
Price Change: +0.30 (1.20%)
As of 03/26/2025 01:00 AM ET

This chart shows the closing price history over time for CYTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Cyclo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Rafael Holdings, Inc.Major ShareholderBuy4,000,000$1.25$5,000,000.006,514,970View SEC Filing Icon  
4/20/2023Jeffrey TateCOOBuy29,941$0.71$21,258.1162,101View SEC Filing Icon  
4/20/2023Markus SiegerDirectorBuy59,881$0.71$42,515.51161,051View SEC Filing Icon  
4/20/2023N. Scott FineCEOBuy299,402$0.71$212,575.42444,402View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

68.55% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2025Two Sigma Securities LLC42,541$25K0.0%N/A0.148%Search for SEC Filing on Google Icon
2/7/2025EPIQ Capital Group LLC689,447$0.41M0.1%-6.8%2.396%Search for SEC Filing on Google Icon
8/10/2024EPIQ Capital Group LLC817,270$1.04M0.4%-4.3%2.856%Search for SEC Filing on Google Icon
2/15/2024Founders Fund V Management LLC480,708$0.76M80.8%N/A2.115%Search for SEC Filing on Google Icon
2/15/2024Founders Fund VI Management LLC110,023$0.18M1.4%N/A0.484%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204%Search for SEC Filing on Google Icon
8/16/2021State Street Corp44,700$0.46M0.0%N/A0.703%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More on Cyclo Therapeutics

Today's Range

Now: $0.72
Low: $0.72
High: $0.72

50 Day Range

MA: $0.72
Low: $0.72
High: $0.72

52 Week Range

Now: $0.72
Low: $0.55
High: $1.45

Volume

N/A

Average Volume

585,177 shs

Market Capitalization

$23.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A